Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1962 1
1963 2
1964 2
1965 1
1966 1
1967 2
1968 1
1975 1
1976 1
1978 2
1979 1
1982 2
1983 2
1985 1
1988 2
1989 1
1993 1
2004 1
2007 1
2009 1
2011 4
2012 2
2013 3
2014 3
2015 7
2016 6
2017 10
2018 18
2019 6
2020 16
2021 9
2022 5
2023 6
2024 4
2025 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

118 results

Results by year

Filters applied: . Clear all
Page 1
Genotypic and phenotypic characterisation of respiratory syncytial virus after nirsevimab breakthrough infections: a large, multicentre, observational, real-world study.
Fourati S, Reslan A, Bourret J, Casalegno JS, Rahou Y, Chollet L, Pillet S, Tremeaux P, Dossou NC, Gault E, Salmona M, Imbert-Marcille BM, Mirand A, Larrat S, Moisan A, Marot S, Schnuriger A, Veyrenche N, Engelmann I, Handala L, Henry A, Stephan V, Brichler S, Avettand-Fenoel V, Zemali N, Lefeuvre C, Pronier C, Deroche L, Jaffar-Bandjee MC, Mouna L, Francois C, Regueme A, Hartard C, Rogez S, Gallais F, Ly A, Rodriguez C, Dos Santos G, Simon-Loriere E, Schwartz O, Buchrieser J, Pawlotsky JM, Lemoine F, Audureau E, Rameix-Welti MA; POLYRES investigators. Fourati S, et al. Lancet Infect Dis. 2025 Mar;25(3):301-311. doi: 10.1016/S1473-3099(24)00570-X. Epub 2024 Oct 14. Lancet Infect Dis. 2025. PMID: 39419046
Clinical phenotypes and outcomes associated with SARS-CoV-2 Omicron sublineage JN.1 in critically ill COVID-19 patients: a prospective, multicenter cohort study in France, November 2022 to January 2024.
de Prost N, Audureau E, Guillon A, Handala L, Préau S, Guigon A, Uhel F, Le Hingrat Q, Delamaire F, Grolhier C, Tamion F, Moisan A, Darreau C, Thomin J, Contou D, Henry A, Daix T, Hantz S, Saccheri C, Giordanengo V, Pham T, Chaghouri A, Bay P, Pawlotsky JM, Fourati S; SEVARVIR investigators. de Prost N, et al. Ann Intensive Care. 2024 Jun 28;14(1):101. doi: 10.1186/s13613-024-01319-w. Ann Intensive Care. 2024. PMID: 38940865 Free PMC article.
Long-term efficacy and safety of etravirine-containing regimens in a real-life cohort of treatment-experienced HIV-1-infected patients.
Allavena C, Katlama C, Cotte L, Roger PM, Delobel P, Cheret A, Duvivier C, Poizot-Martin I, Hoen B, Cabie A, Cheret A, Lahoulou R, Raffi F, Pugliese P; Dat’AIDS Study group. Allavena C, et al. Infect Dis (Lond). 2016;48(5):392-8. doi: 10.3109/23744235.2015.1133927. Epub 2016 Jan 13. Infect Dis (Lond). 2016. PMID: 26757613 Clinical Trial.
Limited Weight Impact After Switching From Boosted Protease Inhibitors to Dolutegravir in Persons With Human Immunodeficiency Virus With High Cardiovascular Risk: A Post Hoc Analysis of the 96-Week NEAT-022 Randomized Trial.
Waters L, Assoumou L, González-Cordón A, Rusconi S, Domingo P, Gompels M, de Wit S, Raffi F, Stephan C, Masiá M, Rockstroh J, Katlama C, Behrens GMN, Moyle G, Johnson M, Fox J, Stellbrink HJ, Guaraldi G, Florence E, Esser S, Gatell JM, Pozniak A, Martínez E; NEAT 022 Study Group. Waters L, et al. Clin Infect Dis. 2023 Mar 4;76(5):861-870. doi: 10.1093/cid/ciac827. Clin Infect Dis. 2023. PMID: 36259527 Free PMC article. Clinical Trial.
118 results